Leverage down and revenues up for Wiltshire’s Alliance Pharma
Alliance Pharma (APH), which has its UK headquarters in Chippenham, saw revenues up 6 per cent at £182.7m for the year ended 31 December 2023.
Growth has been driven by strong consumer demand, particularly in China, for Kelo-Cote scar treatment products and Nizoral anti-dandruff shampoo.
The company acquired both ScarAway and the US rights to Kelo-Cote last year, while reducing its leverage.
It continues to focus on its core consumer healthcare business, which the board anticipates will grow at a rate above that of the broader market.
Visit Hampshire Biz News for bright, upbeat and positive business news from the county
This will be driven by increased investment in sales and marketing throughout 2024.
Peter Butterfield, CEO of Alliance, said: “Our portfolio continues to provide a robust platform from which to grow our consumer healthcare brands.
“In 2023, we delivered record revenues as we launched new advertising campaigns to accelerate organic sales growth whilst bringing new, innovative products to market.
“Our global ecommerce business is building strongly, as we entered several new, high growth geographies in 2023, and look to enter more this year.
“We remain confident in our long-term performance as we focus our resources on those market segments in which we already have a strong presence and expertise in order to drive solid organic revenue growth.”
The group’s audited results will be announced this March.
Read more - Region's businesses urged to seize £82 billion Horizon Europe funding opportunities
